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Finally, it is obvious that together we agree that color M-mode
Doppler is a new and interesting noninvasive method for the evalua-
tion of diastolic function.
ANNE MARIE DUVAL-MOULIN, MD
Service de Cardiologie
Hopital Henri Mondor
51 Avenue du Marechal De Lattre de Tassigny
94010 Creteil, France
References
1. Takatsuji H, Mikami T, Urasawa K, et al. A new approach for evaluation of left ventricular
diastolic function: spatial and temporal analysis of left ventricular filling flow propagation
by color M-mode Doppler echocardiography. J Am Coll Cardiol 1996;27:365–71.
2. Stugaard M, Smiseth OA, Risoe C, Ihlen H. Intraventricular early diastolic filling during
acute myocardial ischemia: assessment by multigated color M-mode Doppler echocardi-
ography. Circulation 1993;88:2705–13.
3. Brun P, Tribouilloy C, Duval AM, et al. Left ventricular flow propagation during early
filling is related to wall relaxation: a color M-mode Doppler analysis. J Am Coll Cardiol
1992;20:420–32.
4. Duval-Moulin AM, Dupouy P, Brun P, et al. Alteration of left ventricular diastolic function
during coronary angioplasty-induced ischemia: a color M-mode Doppler study. J Am Coll
Cardiol 1997;29:1246–55.
Is Pharmacologic Cardioversion of Atrial
Fibrillation Really Preferable to
Electrical Cardioversion?
Harjai et al. (1), in a nonrandomized study, conclude that patients
undergoing electrical cardioversion of atrial fibrillation (AF) display a
“greater degree and longer duration” of mechanical atrial dysfunction
than those who convert pharmacologically or spontaneously. The authors
strongly imply that this finding is a result of the mode of cardioversion.
However, examination of their data reveals that this conclusion is unsup-
ported and, indeed, that an absence of effect is more likely.
There are several flaws in the authors’ analyses and logic. We
would first question whether it is valid, in such a small study of
cardioversion of atrial fibrillation, to include patients who spontane-
ously revert to sinus rhythm. Spontaneous conversions often occur in
the first week of the arrhythmia (2). In a group with a median duration
in excess of 1 month, inclusion of spontaneous convertors with pharma-
cologic converters may bias the data in favor of the latter because, as the
authors point out, a duration of AF ,7 to 14 days has been previously
shown to be associated with better postconversion atrial recovery. Indeed,
reference to Table 1 indicates that almost twice as many patients in the
nonelectrical converter group had an arrhythmia duration ,28 days—a
difference that fails to reach statistical significance only on the basis of the
very small numbers in the former group.
The arbitrary division of AF duration into those with a duration
,28 or .28 days is also problematic. Because previous studies have
demonstrated that an AF duration ,14 days is associated with less
depression of postreversion A wave height (3), the authors should have
analyzed the effects of a shorter arrhythmia duration on A wave
recovery. Indeed, the use of AF duration as a continuous, rather than
a dichotomous, variable would have better elucidated the role of
duration of AF on atrial function.
Multivariate analysis is generally accepted as the “gold” standard in
determining whether a variable is truly associated with an outcome.
When adjusted for several other clinical variables (AF duration, left
atrial size and ejection fraction), the authors state that the mode of
cardioversion was not associated with recovery of atrial electrome-
chanical function, yet they seem to ignore this finding and conclude
from “bivariate analysis” that “only the mode of cardioversion was
seen to have any impact on the recovery of atrial function.”
Finally, it is in our opinion, inaccurate to categorize this study as a
comparison between patients undergoing either pharmacologic or
electrical cardioversion. Presumably, many of the patients who subse-
quently underwent electrical cardioversion had been prescribed an
antiarrhythmic agent either in an attempt to convert the arrhythmia or
to maintain sinus rhythm after cardioversion. If this is so, then the
study is predominantly a comparison of patients who responded to
pharmacologic agents with those in whom pharmacologic conversion
failed. Seen in this light, attributing postreversion atrial stunning to the
mode of reversion is inaccurate.
Whether pharmacologic cardioversion of AF produces less atrial
mechanical dysfunction than electrical cardioversion is an interesting
question that may have some bearing on postconversion risk of
thrombus formation. However, the answer to this question will require
a randomized trial of immediate, drug-free electrical conversion
compared with pharmacologic conversion. Failure to convert, either
electrically or pharmacologically, will have to be treated as failure to
recover mechanical atrial function. To retain a high likelihood of
pharmacologic conversion, entry should probably be limited to those
patients with a short (,7 or ,14 days) arrhythmia duration. Only the
results of such a study can give meaningful answers to the question of
whether the atrium really cares how sinus rhythm is restored (4).
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Reply
We agree with Falk and colleagues that a randomized trial of electrical
versus pharmacologic cardioversion would be the best way to assess the
impact of mode of cardioversion on postcardioversion atrial mechan-
ical dysfunction. Although our study (1) was not a randomized trial, it
represents the only attempt so far to address this issue after multivar-
iate adjustment for other clinical variables that could potentially
influence postcardioversion atrial function. Of all the variables tested,
only the mode of cardioversion was seen to have any influence on the
recovery of atrial function. It is noteworthy that the delay in mechan-
ical recovery of atrial function that was associated with electrical (vs.
nonelectrical) cardioversion was significant after adjustment for pa-
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